Protagonist Therapeutics, Inc Retained Earnings
Protagonist Therapeutics, Inc (PTGX) had Retained Earnings of -$304.04 million as of 2026-06-30, per its 10-Q filed 2026-08-05.
Financial Statements › Balance Sheet › Equity › Equity, Attributable to Parent
us-gaap:RetainedEarningsAccumulatedDeficit · last filed 2026-08-05
- 2026-06-30: Retained Earnings (Accumulated Deficit) -$304.04M.
- 2026-03-31: Retained Earnings (Accumulated Deficit) -$466.89M.
- 2025-12-31: Retained Earnings (Accumulated Deficit) -$470.67M.
- 2025-09-30: Retained Earnings (Accumulated Deficit) -$426.29M.
| Period end | Retained Earnings (Accumulated Deficit) |
|---|---|
| 2026-06-30 | -$304.04M 10-Q · filed 2026-08-05 |
| 2026-03-31 | -$466.89M 10-Q · filed 2026-05-05 |
| 2025-12-31 | -$470.67M 10-Q · filed 2026-08-05 |
| 2025-09-30 | -$426.29M 10-Q · filed 2025-11-06 |
| 2025-06-30 | -$386.95M 10-Q · filed 2025-08-06 |
| 2025-03-31 | -$352.18M 10-Q · filed 2025-05-06 |
| 2024-12-31 | -$340.52M 10-K · filed 2026-02-25 |
| 2024-09-30 | -$472.20M 10-Q · filed 2024-11-07 |
| 2024-06-30 | -$438.99M 10-Q · filed 2024-08-06 |
| 2024-03-31 | -$408.37M 10-Q · filed 2024-05-07 |
| 2023-12-31 | -$615.71M 10-K · filed 2025-02-21 |
| 2023-09-30 | -$643.04M 10-Q · filed 2023-11-02 |
| 2023-06-30 | -$608.94M 10-Q · filed 2023-08-03 |
| 2023-03-31 | -$570.48M 10-Q · filed 2023-05-04 |
| 2022-12-31 | -$536.75M 10-K · filed 2024-02-27 |
| 2022-09-30 | -$502.56M 10-Q · filed 2022-11-08 |
| 2022-06-30 | -$471.33M 10-Q · filed 2022-08-04 |
| 2022-03-31 | -$430.29M 10-Q · filed 2022-05-05 |
| 2021-12-31 | -$409.36M 10-K · filed 2023-03-15 |
| 2021-09-30 | -$372.45M 10-Q · filed 2021-11-03 |
| 2021-06-30 | -$338.65M 10-Q · filed 2021-08-04 |
| 2021-03-31 | -$307.81M 10-Q · filed 2021-05-04 |
| 2020-12-31 | -$283.81M 10-K · filed 2022-02-28 |
| 2020-09-30 | -$264.93M 10-Q · filed 2020-11-04 |
| 2020-06-30 | -$257.16M 10-Q · filed 2020-08-06 |
| 2020-03-31 | -$237.74M 10-Q · filed 2020-05-07 |
| 2019-12-31 | -$217.66M 10-K · filed 2021-03-10 |
| 2019-09-30 | -$200.16M 10-Q · filed 2019-11-06 |
| 2019-06-30 | -$183.75M 10-Q · filed 2019-08-07 |
| 2019-03-31 | -$154.58M 10-Q · filed 2019-05-08 |
| 2018-12-31 | -$140.47M 10-K · filed 2020-03-10 |
| 2018-09-30 | -$126.61M 10-Q · filed 2018-11-06 |
| 2018-06-30 | -$117.87M 10-Q · filed 2018-08-07 |
| 2018-03-31 | -$109.21M 10-Q · filed 2018-05-09 |
| 2017-12-31 | -$101.55M 10-K · filed 2019-03-12 |
| 2017-09-30 | -$98.50M 10-Q · filed 2017-11-07 |
| 2017-06-30 | -$93.67M 10-Q · filed 2017-08-08 |
| 2017-03-31 | -$78.69M 10-Q · filed 2017-05-10 |
| 2016-12-31 | -$64.59M 10-K · filed 2018-03-07 |
| 2016-09-30 | -$53.34M 10-Q · filed 2016-11-14 |
| 2016-06-30 | -$46.26M 10-Q · filed 2016-09-15 |
| 2015-12-31 | -$27.42M 10-K · filed 2017-03-07 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| TG THERAPEUTICS, INC. (TGTX) | United States | $8.805B | 19.05 |
| CYTOKINETICS INC (CYTK) | United States | $9.130B | -11.86 |
| ARROWHEAD PHARMACEUTICALS, INC. (ARWR) | United States | $9.331B | -42.28 |
| Praxis Precision Medicines, Inc. (PRAX) | United States | $7.884B | -27.60 |
| Structure Therapeutics Inc. (GPCR) | United States | $7.710B | -53.41 |
| Spyre Therapeutics, Inc. (SYRE) | United States | $7.685B | -43.69 |
| Axsome Therapeutics, Inc. (AXSM) | United States | $10.274B | -66.82 |
| IONIS PHARMACEUTICALS INC (IONS) | United States | $7.277B | -23.25 |
| Alkermes plc. (ALKS) | $6.844B | 132.74 | |
| RHYTHM PHARMACEUTICALS, INC. (RYTM) | United States | $6.771B | -37.20 |